CyPep-1 is under clinical development by Cytovation and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CyPep-1’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CyPep-1 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CyPep-1 overview

CyPep-1 is under development for the treatment of cutaneous warts (papillomas) caused by human papilloma virus, skin tumors, melanoma, head and neck squamous cell carcinoma (HNSCC) and triple-negative breast cancer (TNBC) and cancers and recurrent respiratory papillomatosis (RRP). It is administered topically as cream for warts and intratumorally and subcutaneous for solid tumors and lymphoma. CyPep-1 is a tumor specific, cytotoxic peptide with extreme lipid penetrating properties. CyPep-1 targets the wart cells and induces rapid necrotic cell death. The drug candidate was also under development for the treatment of multi-resistant bacterial infections such as E.coli infections.

Cytovation overview

Cytovation is a biotech company that develops novel therapeutic agents for skin diseases and infections. The company’s lead candidate includes CyPep-1, a novel peptide and an anti-bacterial compound. Its CyPep-1 is developed for skin disorders such as papilloma diseases, tumors of skin warts caused from HPV transfected transformed keratinocytes and cypep-1 selectivly targets and lyses skin tumor cells due to negative chargeon cell membrenes. Cytovation targets the wart cells and destroys the transformed cancer cells and a wide range of drug resistant bacterias such as E-coli bacterias. The company partners with pharmaceutical companies, scientific institutions and research organizations. Cytovation is headquartered in Bergen, Norway.

Quick View CyPep-1 LOA Data

Report Segments
  • Innovator
Drug Name
  • CyPep-1
Administration Pathway
  • Intratumor
  • Subcutaneous
  • Topical
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.